HENDERSON MICHAEL THOMAS 4
4 · Apogee Therapeutics, Inc. · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Apogee Therapeutics CEO Michael Henderson Sells Shares
What Happened
Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, sold a total of 20,000 shares of APGE stock in open-market transactions on March 11, 2026. The three reported dispositions were: 8,363 shares at a weighted average price of $74.29 ($621,287), 8,219 shares at $74.83 ($615,028), and 3,418 shares at $75.86 ($259,289), for combined gross proceeds of about $1,495,604 (≈ $74.78 per share). These were sales (code S), not purchases.
Key Details
- Transaction date: March 11, 2026; Form 4 filed March 13, 2026 (appears timely).
- Total shares sold: 20,000; total proceeds: ~$1.50 million.
- Reported per-lot details and footnotes:
- F1: Transactions executed pursuant to a Rule 10b5-1 trading plan adopted August 13, 2025.
- F2–F4: Each reported price is a weighted average for multiple trades; price ranges reported were $73.525–$74.520, $74.525–$75.400, and $75.585–$76.480 respectively. The filer offers to provide breakdowns by individual trade price on request.
- Shares owned after the transactions: not specified in the provided filing excerpt.
Context
Sales executed under a pre-established 10b5-1 plan are generally considered routine because the plan sets terms in advance; they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases typically carry clearer signals of insider confidence than routine sales; these filings are primarily disclosure of insider liquidity.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-11$74.29/sh−8,363$621,287→ 1,164,624 total - Sale
Common Stock
[F1][F3]2026-03-11$74.83/sh−8,219$615,028→ 1,156,405 total - Sale
Common Stock
[F1][F4]2026-03-11$75.86/sh−3,418$259,289→ 1,152,987 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.525 to $74.520, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.525 to $75.400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.585 to $76.480, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.